{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:05:33Z","timestamp":1790795133271,"version":"4.1.0"},"reference-count":126,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017804","name":"City of Hope","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017804","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Opinion statement<\/jats:title>\n                  <jats:p>Nasopharyngeal carcinoma (NPC) is distinct in its anatomic location and biology from other epithelial head and neck cancer (HNC). There are 3 WHO subtypes, which considers the presence of Epstein-Barr virus (EBV) and other histopathology features. Despite the survival benefit obtained from modern treatment modalities and techniques specifically in the local and locally advanced setting, a number of patients with this disease will recur and subsequently die of distant metastasis, locoregional relapse, or both. In the recurrent setting, the ideal therapy approach continues to be a topic of discussion and current recommendations are platinum-based combination chemotherapy. Phase III clinical trials which led to the approval of pembrolizumab or nivolumab for head and neck squamous cell carcinoma (HNSCC) specifically excluded NPC. No immune checkpoint inhibitor therapy, to date, has been approved by the FDA to treat NPC although the National Comprehensive Cancer Network (NCCN) recommendations do include use of these agents. Hence, this remains the major challenge for treatment options. Nasopharyngeal carcinoma is challenging as it is really 3 different diseases, and much research is required to determine best options and sequencing of those options. This article is going to address the data to date and discuss ongoing research in EBV + and EBV \u2013 inoperable recurrent\/metastatic NPC patients.<\/jats:p>","DOI":"10.1007\/s11864-023-01101-3","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T08:02:11Z","timestamp":1686816131000},"page":"1138-1166","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":99,"title":["Recurrent\/Metastatic Nasopharyngeal Carcinoma Treatment from Present to Future: Where Are We and Where Are We Heading?"],"prefix":"10.1007","volume":"24","author":[{"given":"Juan Jose","family":"Juarez-Vignon Whaley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Afkhami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mykola","family":"Onyshchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erminia","family":"Massarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagus","family":"Sampath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arya","family":"Amini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria M.","family":"Villaflor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,15]]},"reference":[{"key":"1101_CR1","unstructured":"Nasopharynx GLOBOCAN 2020 [Internet]. World Health Organization. 2020. Available from:\u00a0https:\/\/gco.iarc.fr\/today\/data\/factsheets\/cancers\/4-Nasopharynx-fact-sheet.pdf. Accessed Feb 2, 2023"},{"key":"1101_CR2","doi-asserted-by":"crossref","unstructured":"Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging. CA Cancer J Clin. 2017;67(2):93\u20139.","DOI":"10.3322\/caac.21388"},{"key":"1101_CR3","doi-asserted-by":"crossref","unstructured":"Shanmugaratnam K, Sobin LH. The world health organization histological classification of tumours of the upper respiratory tract and ear. A commentary on the second edition. Cancer. 1993;71(8):2689\u201397.","DOI":"10.1002\/1097-0142(19930415)71:8<2689::AID-CNCR2820710843>3.0.CO;2-H"},{"issue":"3","key":"1101_CR4","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/(SICI)1097-0142(19980801)83:3<582::AID-CNCR29>3.0.CO;2-R","volume":"83","author":"JE Marks","year":"1998","unstructured":"Marks JE, Phillips JL, Menck HR. The national cancer data base report on the relationship of race and national origin to the histology of nasopharyngeal carcinoma. Cancer. 1998;83(3):582\u20138.","journal-title":"Cancer."},{"key":"1101_CR5","doi-asserted-by":"publisher","unstructured":"Almobarak AA, Jebreel AB, Abu-Zaid A. Molecular targeted therapy in the management of recurrent and metastatic nasopharyngeal carcinoma: a comprehensive literature review. Cureus. 2019;11(3). https:\/\/doi.org\/10.7759\/cureus.4210","DOI":"10.7759\/cureus.4210"},{"key":"1101_CR6","doi-asserted-by":"crossref","unstructured":"Raab-Traub N. Epstein\u2013Barr virus in the pathogenesis of NPC. Cancer Biol [Internet]. 2002;12:431\u201341. Available from: file:\/\/\/C:\/Users\/ASUS\/Desktop\/RujukanPhD\/BRCA\/BRCA1methylation-catteau2002.pdf","DOI":"10.1016\/S1044579X0200086X"},{"key":"1101_CR7","doi-asserted-by":"publisher","first-page":"149","DOI":"10.14694\/EdBook_AM.2014.34.149","volume":"34","author":"R Raghupathy","year":"2014","unstructured":"Raghupathy R, Hui EP, Chan ATC. Epstein-Barr virus as a paradigm in nasopharyngeal cancer: from lab to clinic. Am Soc Clin Oncol Educ B. 2014;34:149\u201353.","journal-title":"Am Soc Clin Oncol Educ B."},{"issue":"17","key":"1101_CR8","doi-asserted-by":"publisher","first-page":"6147","DOI":"10.1002\/cam4.3301","volume":"9","author":"W Qu","year":"2020","unstructured":"Qu W, Li S, Zhang M, Qiao Q. Pattern and prognosis of distant metastases in nasopharyngeal carcinoma: a large-population retrospective analysis. Cancer Med. 2020;9(17):6147\u201358.","journal-title":"Cancer Med"},{"issue":"1","key":"1101_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-20308-8","volume":"12","author":"M Lechner","year":"2021","unstructured":"Lechner M, Schartinger VH, Steele CD, Nei WL, Ooft ML, Schreiber LM, et al. Somatostatin receptor 2 expression in nasopharyngeal cancer is induced by Epstein Barr virus infection: impact on prognosis, imaging and therapy. Nat Commun. 2021;12(1):1\u201311.","journal-title":"Nat Commun."},{"issue":"5","key":"1101_CR10","doi-asserted-by":"publisher","first-page":"425","DOI":"10.2217\/fon-2016-0410","volume":"13","author":"JW Chan","year":"2017","unstructured":"Chan JW, Parvathaneni U, Yom SS. Reducing radiation-related morbidity in the treatment of nasopharyngeal carcinoma. Futur Oncol. 2017;13(5):425\u201331.","journal-title":"Futur Oncol."},{"issue":"3","key":"1101_CR11","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/COC.0b013e31820dbdcc","volume":"35","author":"B You","year":"2012","unstructured":"You B, Le Tourneau C, Chen EX, Wang L, Jarvi A, Bharadwaj RR, et al. A phase II trial of erlotinib as maintenance treatment after gemcitabine plus platinum-based chemotherapy in patients with recurrent and\/or metastatic nasopharyngeal carcinoma. Am J Clin Oncol Cancer Clin Trials. 2012;35(3):255\u201360.","journal-title":"Am J Clin Oncol Cancer Clin Trials."},{"key":"1101_CR12","doi-asserted-by":"publisher","unstructured":"Li YY, Chung GTY, Lui VWY, To KF, Ma BBY, Chow C, et al. Exome and genome sequencing of nasopharynx cancer identifies NF-? B pathway activating mutations. Nat Commun [Internet]. 2017;8:1\u201310. Available from: https:\/\/doi.org\/10.1038\/ncomms14121.","DOI":"10.1038\/ncomms14121"},{"issue":"August","key":"1101_CR13","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.semcancer.2019.09.006","volume":"61","author":"CM Tsang","year":"2020","unstructured":"Tsang CM, Lui VWY, Bruce JP, Pugh TJ, Lo KW. Translational genomics of nasopharyngeal cancer. Semin Cancer Biol. 2020;61(August):84\u2013100.","journal-title":"Semin Cancer Biol."},{"key":"1101_CR14","unstructured":"Sanger Institute. Catalog Of Somatic Mutations In Cancer [Internet]. Available from:\u00a0https:\/\/cancer.sanger.ac.uk\/cosmic\/browse\/tissue. Accessed Feb 2, 2023"},{"issue":"1","key":"1101_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-021-24348-6","volume":"12","author":"JP Bruce","year":"2021","unstructured":"Bruce JP, To KF, Lui VWY, Chung GTY, Chan YY, Tsang CM, et al. Whole-genome profiling of nasopharyngeal carcinoma reveals viral-host co-operation in inflammatory NF-\u03baB activation and immune escape. Nat Commun. 2021;12(1):1\u201315.","journal-title":"Nat Commun"},{"issue":"9","key":"1101_CR16","doi-asserted-by":"publisher","first-page":"6035","DOI":"10.3390\/curroncol29090475","volume":"29","author":"X Liu","year":"2022","unstructured":"Liu X, Deng Y, Huang Y, Ye J, Xie S, He Q, et al. Nasopharyngeal carcinoma progression: accumulating genomic instability and persistent Epstein-Barr virus infection. Curr Oncol. 2022;29(9):6035\u201352.","journal-title":"Curr Oncol"},{"issue":"6","key":"1101_CR17","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1002\/ijc.20051","volume":"109","author":"AKF Lo","year":"2004","unstructured":"Lo AKF, Huang DP, Lo KW, Chui YL, Li HM, Pang JCS, et al. Phenotypic alterations induced by the Hong Kong-prevalent Epstein-Barr virus-encoded LMP1 variant (2117-LMP1) in nasopharyngeal epithelial cells. Int J Cancer. 2004;109(6):919\u201325.","journal-title":"Int J Cancer."},{"issue":"1","key":"1101_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1750-9378-5-16","volume":"5","author":"SH Hutajulu","year":"2010","unstructured":"Hutajulu SH, Hoebe EK, Verkuijlen SAWM, Fachiroh J, Hariwijanto B, Haryana SM, et al. Conserved mutation of Epstein-Barr virus-encoded BamHI-A Rightward Frame-1 (BARF1) gene in Indonesian nasopharyngeal carcinoma. Infect Agent Cancer. 2010;5(1):1\u201312.","journal-title":"Infect Agent Cancer."},{"key":"1101_CR19","doi-asserted-by":"publisher","unstructured":"Fountzilas G, Psyrri A, Giannoulatou E, Tikas I, Manousou K, Rontogianni D, et al. Prevalent somatic BRCA1 mutations shape clinically relevant genomic patterns of nasopharyngeal carcinoma in Southeast Europe. Int J Cancer [Internet]. 2018;142(1):66\u201380. Available from: https:\/\/doi.org\/10.1002\/ijc.31023.","DOI":"10.1002\/ijc.31023."},{"issue":"40","key":"1101_CR20","doi-asserted-by":"publisher","first-page":"11283","DOI":"10.1073\/pnas.1607606113","volume":"113","author":"H Zheng","year":"2016","unstructured":"Zheng H, Dai W, Cheung AKL, Ko JMY, Kan R, Wong BWY, et al. Whole-exome sequencing identifies multiple loss-of-function mutations of NF-\u03baB pathway regulators in nasopharyngeal carcinoma. Proc Natl Acad Sci U S A. 2016;113(40):11283\u20138.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"1101_CR21","doi-asserted-by":"publisher","unstructured":"Dietlein F, Thelen L, Reinhardt HC. Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches. Trends Genet [Internet]. 2014;30(8):326\u201339. Available from: https:\/\/doi.org\/10.1016\/j.tig.2014.06.003.","DOI":"10.1016\/j.tig.2014.06.003."},{"key":"1101_CR22","doi-asserted-by":"crossref","unstructured":"Murciano-Goroff YR, Schram AM, Rosen EY, Won H, Gong Y, Noronha AM, et al. Reversion mutations in germline BRCA1\/2-mutant tumors reveal a BRCA-mediated phenotype in non-canonical histologies. Nat Commun [Internet]. 2022;13(1):7182. Available from:\u00a0http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/36418296. Accessed Feb 2, 2023","DOI":"10.1038\/s41467-022-34109-8"},{"issue":"4","key":"1101_CR23","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1158\/1078-0432.CCR-17-1327","volume":"24","author":"BM Norquist","year":"2018","unstructured":"Norquist BM, Brady MF, Harrell MI, Walsh T, Lee MK, Gulsuner S, et al. Mutations in homologous recombination genes and outcomes in ovarian carcinoma patients in GOG 218: An NRG oncology\/Gynecologic oncology group study. Clin Cancer Res. 2018;24(4):777\u201383.","journal-title":"Clin Cancer Res."},{"issue":"June","key":"1101_CR24","first-page":"1","volume":"12","author":"N Mekonnen","year":"2022","unstructured":"Mekonnen N, Yang H, Shin YK. Homologous recombination deficiency in ovarian, breast, colorectal, pancreatic, non-small cell lung and prostate cancers, and the mechanisms of resistance to PARP inhibitors. Front Oncol. 2022;12(June):1\u201328.","journal-title":"Front Oncol"},{"issue":"7391","key":"1101_CR25","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/nature11005","volume":"483","author":"MJ Garnett","year":"2012","unstructured":"Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature. 2012;483(7391):570\u20135.","journal-title":"Nature."},{"key":"1101_CR26","doi-asserted-by":"crossref","unstructured":"Kayla A Martin, Lena N Lupey, Italo Tempera. Epstein-Barr virus oncoprotein LMP1 mediates epigenetic changes in host gene expression through PARP1. J Virol. 2016;90:8520\u201330.","DOI":"10.1128\/JVI.01180-16"},{"issue":"1","key":"1101_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1750-9378-2-18","volume":"2","author":"S Mattiussi","year":"2007","unstructured":"Mattiussi S, Tempera I, Matusali G, Mearini G, Lenti L, Fratarcangeli S, et al. Inhibition of poly(ADP-ribose)polymerase impairs Epstein Barr virus lytic cycle progression. Infect Agent Cancer. 2007;2(1):1\u20139.","journal-title":"Infect Agent Cancer."},{"key":"1101_CR28","doi-asserted-by":"publisher","unstructured":"Emanuel O, Liu J, Schartinger VH, Nei WL, Chan YY, Tsang CM, et al. Sstr2 in nasopharyngeal carcinoma: relationship with latent ebv infection and potential as a therapeutic target. Cancers (Basel). 2021;13(19). https:\/\/doi.org\/10.3390\/cancers13194944","DOI":"10.3390\/cancers13194944"},{"issue":"1","key":"1101_CR29","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s00259-014-2905-5","volume":"42","author":"VH Schartinger","year":"2015","unstructured":"Schartinger VH, Dud\u00e1s J, Url C, Reinold S, Virgolini IJ, Kroiss A, et al. 68Ga-DOTA0-Tyr3-octreotide positron emission tomography in nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging. 2015;42(1):20\u20134.","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"10","key":"1101_CR30","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/hed.23845","volume":"36","author":"E Leoncini","year":"2014","unstructured":"Leoncini E, Ricciardi W, Cadoni G, Arzani D, Petrelli L, Paludetti G, et al. Adult height and head and neck cancer: a pooled analysis within the INHANCE Consortium. Head Neck. 2014;36(10):1391.","journal-title":"Head Neck"},{"issue":"4","key":"1101_CR31","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1097\/RLU.0000000000001985","volume":"43","author":"M Unterrainer","year":"2018","unstructured":"Unterrainer M, Maihoefer C, Cyran CC, Bartenstein P, Niyazi M, Albert NL. 68Ga-DOTATATE PET\/CT reveals Epstein-Barr virus-associated nasopharyngeal carcinoma in a case of suspected sphenoid wing meningioma. Clin Nucl Med. 2018;43(4):287\u20138.","journal-title":"Clin Nucl Med."},{"issue":"5","key":"1101_CR32","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1007\/s00428-002-0693-y","volume":"441","author":"KS Loh","year":"2002","unstructured":"Loh KS, Waser B, Tan LKS, Ruan RS, Stauffer E, Reubi JC. Somatostatin receptors in nasopharyngeal carcinoma. Virchows Arch. 2002;441(5):444\u20138.","journal-title":"Virchows Arch"},{"key":"1101_CR33","doi-asserted-by":"crossref","unstructured":"Han S, Yeong J, Lim CX, Ang M-K, Lim WTD, Toh CK, et al. Somatostatin receptor 2 expression and clinical significance in pulmonary lymphoepithelioma-like carcinoma. Ann Oncol. 2018;29(October):viii678.","DOI":"10.1093\/annonc\/mdy304.029"},{"issue":"3","key":"1101_CR34","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1056\/NEJMoa1316158","volume":"371","author":"ME Caplin","year":"2014","unstructured":"Caplin ME, Pavel M, \u0106wik\u0142a JB, Phan AT, Raderer M, Sedl\u00e1\u010dkov\u00e1 E, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3):224\u201333.","journal-title":"N Engl J Med."},{"issue":"12","key":"1101_CR35","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1097\/RLU.0000000000002788","volume":"44","author":"W Zhu","year":"2019","unstructured":"Zhu W, Zhang J, Singh A, Kulkarni HR, Baum RP. Metastatic Nasopharyngeal carcinoma treated with intraarterial combined with intravenous peptide receptor radionuclide therapy. Clin Nucl Med. 2019;44(12):989\u201390.","journal-title":"Clin Nucl Med."},{"issue":"6","key":"1101_CR36","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1002\/hed.25104","volume":"40","author":"J Lu","year":"2018","unstructured":"Lu J, Chen XM, Huang HR, Zhao FP, Wang F, Liu X, et al. Detailed analysis of inflammatory cell infiltration and the prognostic impact on nasopharyngeal carcinoma. Head Neck. 2018;40(6):1245\u201353.","journal-title":"Head Neck."},{"key":"1101_CR37","doi-asserted-by":"publisher","unstructured":"Johnson D, Ma BBY. Targeting the PD-1\/ PD-L1 interaction in nasopharyngeal carcinoma. Oral Oncol [Internet]. 2021;113(June 2020):105127. Available from: https:\/\/doi.org\/10.1016\/j.oraloncology.2020.105127.","DOI":"10.1016\/j.oraloncology.2020.105127"},{"issue":"23","key":"1101_CR38","doi-asserted-by":"publisher","first-page":"12189","DOI":"10.18632\/oncotarget.2608","volume":"5","author":"W Fang","year":"2014","unstructured":"Fang W, Zhang J, Hong S, Zhan J, Chen N, Qin T, et al. EBV-driven LMP1 and IFN-\u03b3 up-regulate PD-L1 in nasopharyngeal carcinoma: implications for oncotargeted therapy. Oncotarget. 2014;5(23):12189\u2013202.","journal-title":"Oncotarget."},{"key":"1101_CR39","doi-asserted-by":"publisher","unstructured":"Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet [Internet]. 2019;394(10192):64\u201380. Available from: https:\/\/doi.org\/10.1016\/S0140-6736(19)30956-0.","DOI":"10.1016\/S0140-6736(19)30956-0."},{"key":"1101_CR40","doi-asserted-by":"publisher","unstructured":"Chow JCH, Ngan RKC, Cheung KM, Cho WCS. Immunotherapeutic approaches in nasopharyngeal carcinoma. Expert Opin Biol Ther [Internet]. 2019;19(11):1165\u201372. Available from: https:\/\/doi.org\/10.1080\/14712598.2019.1650910.","DOI":"10.1080\/14712598.2019.1650910."},{"issue":"2","key":"1101_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21037\/cco.2016.03.08","volume":"5","author":"A Jain","year":"2016","unstructured":"Jain A, Chia WK, Toh HC. Immunotherapy for nasopharyngeal cancer-a review. Chinese Clin Oncol. 2016;5(2):1\u201310.","journal-title":"Chinese Clin Oncol."},{"key":"1101_CR42","doi-asserted-by":"publisher","first-page":"175883592210962","DOI":"10.1177\/17588359221096214","volume":"14","author":"J-Y Xu","year":"2022","unstructured":"Xu J-Y, Wei X-L, Wang Y-Q, Wang F-H. Current status and advances of immunotherapy in nasopharyngeal carcinoma. Ther Adv Med Oncol. 2022;14:17588359221096214.","journal-title":"Ther Adv Med Oncol."},{"issue":"36","key":"1101_CR43","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.1200\/JCO.2017.73.3675","volume":"35","author":"C Hsu","year":"2017","unstructured":"Hsu C, Lee SH, Ejadi S, Even C, Cohen RB, Le Tourneau C, et al. Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study. J Clin Oncol. 2017;35(36):4050\u20136.","journal-title":"J Clin Oncol."},{"issue":"2","key":"1101_CR44","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s00280-012-2020-x","volume":"71","author":"C Chen","year":"2013","unstructured":"Chen C, Wang FH, An X, Luo HY, Wang ZQ, Liang Y, et al. Triplet combination with paclitaxel, cisplatin and 5-FU is effective in metastatic and\/or recurrent nasopharyngeal carcinoma. Cancer Chemother Pharmacol. 2013;71(2):371\u20138.","journal-title":"Cancer Chemother Pharmacol."},{"key":"1101_CR45","doi-asserted-by":"publisher","unstructured":"Zhang L, Huang Y, Hong S, Yang Y, Yu G, Jia J, et al. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. Lancet [Internet]. 2016;388(10054):1883\u201392. Available from: https:\/\/doi.org\/10.1016\/S0140-6736(16)31388-5.","DOI":"10.1016\/S0140-6736(16)31388-5."},{"issue":"29","key":"1101_CR46","doi-asserted-by":"publisher","first-page":"3273","DOI":"10.1200\/JCO.21.00396","volume":"39","author":"S Hong","year":"2021","unstructured":"Hong S, Zhang Y, Yu G, Peng P, Peng J, Jia J, et al. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin as first-line therapy for recurrent or metastatic nasopharyngeal carcinoma: final overall survival analysis of GEM20110714 Phase III Study original report. J Clin Oncol. 2021;39(29):3273\u201382.","journal-title":"J Clin Oncol."},{"issue":"8","key":"1101_CR47","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1038\/s41416-018-0026-9","volume":"118","author":"B Ma","year":"2018","unstructured":"Ma B, Hui EP, King A, Leung SF, Kam MKM, Mo F, et al. Prospective evaluation of plasma Epstein-Barr virus DNA clearance and fluorodeoxyglucose positron emission scan in assessing early response to chemotherapy in patients with advanced or recurrent nasopharyngeal carcinoma. Br J Cancer. 2018;118(8):1051\u20135.","journal-title":"Br J Cancer"},{"issue":"10","key":"1101_CR48","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1007\/s00432-012-1219-x","volume":"138","author":"Y Jin","year":"2012","unstructured":"Jin Y, Cai XY, Shi YX, Xia XY, Cai YC, Cao Y, et al. Comparison of five cisplatin-based regimens frequently used as the first-line protocols in metastatic nasopharyngeal carcinoma. J Cancer Res Clin Oncol. 2012;138(10):1717\u201325.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"15","key":"1101_CR49","doi-asserted-by":"publisher","first-page":"3562","DOI":"10.1200\/JCO.2005.01.057","volume":"23","author":"MK Gibson","year":"2005","unstructured":"Gibson MK, Li Y, Murphy B, Hussain MHA, DeConti RC, Ensley J, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2005;23(15):3562\u20137.","journal-title":"J Clin Oncol."},{"issue":"13","key":"1101_CR50","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1016\/S0959-8049(98)00280-9","volume":"34","author":"W Yeo","year":"1998","unstructured":"Yeo W, Leung TWT, Chan ATC, Chiu SKW, Yu P, Mok TSK, et al. A phase II study of combination paclitaxel and carboplatin in advanced nasopharyngeal carcinoma. Eur J Cancer. 1998;34(13):2027\u201331.","journal-title":"Eur J Cancer"},{"issue":"2","key":"1101_CR51","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1023\/A:1008390929826","volume":"10","author":"EH Tan","year":"1999","unstructured":"Tan EH, Khoo KS, Wee J, Fong KW, Lee KS, Lee KM, et al. Phase II trial of a paclitaxel and carboplatin combination in Asian patients with metastatic nasopharyngeal carcinoma. Ann Oncol. 1999;10(2):235\u20137.","journal-title":"Ann Oncol"},{"key":"1101_CR52","doi-asserted-by":"crossref","unstructured":"Liu GY, Li WZ, Wang DS, Liang H, Lv X, Ye YF, Zhao C, Ke LR, Lv SH, Lu N, Bei WX, Cai ZC, Chen X, Liang CX, Guo X, Xia WX XY. Effect of capecitabine maintenance therapy plus best supportive care vs best supportive care alone on progression-free survival among patients with newly diagnosed metastatic nasopharyngeal carcinoma who had received induction chemotherapy: a Phase 3 Rand. JAMA Oncol. 2022;1;8(4):553\u201361.","DOI":"10.1001\/jamaoncol.2021.7366"},{"issue":"15","key":"1101_CR53","doi-asserted-by":"publisher","first-page":"3568","DOI":"10.1200\/JCO.2005.02.147","volume":"23","author":"ATC Chan","year":"2005","unstructured":"Chan ATC, Hsu MM, Goh BC, Hui EP, Liu TW, Millward MJ, et al. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol. 2005;23(15):3568\u201376.","journal-title":"J Clin Oncol."},{"issue":"4","key":"1101_CR54","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S1368-8375(02)00120-3","volume":"39","author":"DTT Chua","year":"2003","unstructured":"Chua DTT, Sham JST, Au GKH. A phase II study of capecitabine in patients with recurrent and metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy. Oral Oncol. 2003;39(4):361\u20136.","journal-title":"Oral Oncol."},{"issue":"1","key":"1101_CR55","first-page":"37","volume":"13","author":"E Ciuleanu","year":"2008","unstructured":"Ciuleanu E, Irimie A, Ciuleanu TE, Popita V, Todor NGN. Capecitabine as salvage treatment in relapsed nasopharyngeal carcinoma: a phase II study. J BUON. 2008;13(1):37\u201342.","journal-title":"J BUON"},{"issue":"3","key":"1101_CR56","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/cncr.20802","volume":"103","author":"D Poon","year":"2005","unstructured":"Poon D, Chowbay B, Cheung YB, Leong SS, Tan EH. Phase II study of irinotecan (CPT-11) as salvage therapy for advanced nasopharyngeal carcinoma. Cancer. 2005;103(3):576\u201381.","journal-title":"Cancer"},{"key":"1101_CR57","doi-asserted-by":"publisher","unstructured":"Ngeow J, Lim WT, Leong SS, Ang MK, Toh CK, Gao F, et al. Docetaxel is effective in heavily pretreated patients with disseminated nasopharyngeal carcinoma. Ann Oncol [Internet]. 2011;22(3):718\u201322. Available from: https:\/\/doi.org\/10.1093\/annonc\/mdq425.","DOI":"10.1093\/annonc\/mdq425."},{"issue":"3","key":"1101_CR58","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1023\/A:1008255220284","volume":"9","author":"E Au","year":"1998","unstructured":"Au E, Tan EHAP. Activity of paclitaxel by three-hour infusion in Asian patients with metastatic undifferentiated nasopharyngeal cancer. Ann Oncol. 1998;9(3):327\u20139.","journal-title":"Ann Oncol"},{"key":"1101_CR59","doi-asserted-by":"publisher","unstructured":"Foo KF, Tan EH, Leong SS, Wee JTS, Tan T, Fong KW, et al. Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated type. Ann Oncol [Internet]. 2002;13(1):150\u20136. Available from: https:\/\/doi.org\/10.1093\/annonc\/mdf002.","DOI":"10.1093\/annonc\/mdf002."},{"key":"1101_CR60","doi-asserted-by":"publisher","unstructured":"Lievens Y, Guckenberger M, Gomez D, Hoyer M, Iyengar P, Kindts I, et al. Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document. Radiother Oncol [Internet]. 2020;148:157\u201366. Available from: https:\/\/doi.org\/10.1016\/j.radonc.2020.04.003.","DOI":"10.1016\/j.radonc.2020.04.003."},{"issue":"1","key":"1101_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0146771","volume":"11","author":"W Zheng","year":"2016","unstructured":"Zheng W, Zong J, Huang C, Chen J, Wu J, Chen C, et al. Multimodality treatment may improve the survival rate of patients with metastatic nasopharyngeal carcinoma with good performance status. PLoS ONE. 2016;11(1):1\u201310.","journal-title":"PLoS ONE"},{"key":"1101_CR62","doi-asserted-by":"publisher","unstructured":"Hu J, Kong L, Gao J, Hu W, Guan X, Lu JJ. Use of radiation therapy in metastatic nasopharyngeal cancer improves survival: a SEER analysis. Sci Rep [Internet]. 2017;7(1):1\u20138. Available from: https:\/\/doi.org\/10.1038\/s41598-017-00655-1.","DOI":"10.1038\/s41598-017-00655-1."},{"issue":"8","key":"1101_CR63","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1002\/hed.26130","volume":"42","author":"T Huang","year":"2020","unstructured":"Huang T, Su N, Zhang X, Ma S, Zhong G, Tian X, et al. Systemic chemotherapy and sequential locoregional radiotherapy in initially metastatic nasopharyngeal carcinoma: Retrospective analysis with 821 cases. Head Neck. 2020;42(8):1970\u201380.","journal-title":"Head Neck."},{"key":"1101_CR64","doi-asserted-by":"publisher","unstructured":"Li WZ, Lv SH, Liu GY, Liang H, Guo X, Lv X, et al. Development of a prognostic model to identify the suitable definitive radiation therapy candidates in de novo metastatic nasopharyngeal carcinoma: a real-world study. Int J Radiat Oncol Biol Phys [Internet]. 2021;109(1):120\u201330. Available from: https:\/\/doi.org\/10.1016\/j.ijrobp.2020.08.045.","DOI":"10.1016\/j.ijrobp.2020.08.045."},{"issue":"9","key":"1101_CR65","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1001\/jamaoncol.2020.1808","volume":"6","author":"R You","year":"2020","unstructured":"You R, Liu YP, Huang PY, Zou X, Sun R, He YX, et al. Efficacy and safety of locoregional radiotherapy with chemotherapy vs chemotherapy alone in de novo metastatic nasopharyngeal carcinoma: a multicenter phase 3 randomized clinical trial. JAMA Oncol. 2020;6(9):1345\u201352.","journal-title":"JAMA Oncol"},{"key":"1101_CR66","doi-asserted-by":"crossref","unstructured":"Zhang Y, Tang L long, Li YQ, Liu X, Liu Q, Ma J. Spontaneous remission of residual post-therapy plasma Epstein\u2013Barr virus DNA and its prognostic implication in nasopharyngeal carcinoma: a large-scale, big-data intelligence platform-based analysis. Int J Cancer. 2019;144(9):2313\u20139.","DOI":"10.1002\/ijc.32021"},{"issue":"February","key":"1101_CR67","first-page":"1","volume":"10","author":"L Lai","year":"2021","unstructured":"Lai L, Chen X, Zhang C, Chen X, Chen L, Tian G, et al. Pretreatment plasma EBV-DNA load guides induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal cancer: a meta-analysis. Front Oncol. 2021;10(February):1\u201310.","journal-title":"Front Oncol."},{"issue":"1","key":"1101_CR68","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nrd2781","volume":"8","author":"V Baud","year":"2009","unstructured":"Baud V, Karin M. Is NF-\u03baB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov. 2009;8(1):33\u201340.","journal-title":"Nat Rev Drug Discov."},{"key":"1101_CR69","doi-asserted-by":"publisher","first-page":"8537966","DOI":"10.1155\/2022\/8537966","volume":"2022","author":"J Bian","year":"2022","unstructured":"Bian J, Niu Y, Ma Y, Chen F, Ma N. A review on the application of PD-1 blockade in EBV-associated nasopharyngeal carcinoma immunotherapy. Appl Bionics Biomech. 2022;2022:8537966.","journal-title":"Appl Bionics Biomech"},{"issue":"9","key":"1101_CR70","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1038\/s41591-021-01444-0","volume":"27","author":"HQ Mai","year":"2021","unstructured":"Mai HQ, Chen QY, Chen D, Hu C, Yang K, Wen J, et al. Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial. Nat Med. 2021;27(9):1536\u201343.","journal-title":"Nat Med"},{"key":"1101_CR71","doi-asserted-by":"publisher","unstructured":"Yang Y, Qu S, Li J, Hu C, Xu M, Li W, et al. Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol [Internet]. 2021;22(8):1162\u201374. Available from: https:\/\/doi.org\/10.1016\/S1470-2045(21)00302-8.","DOI":"10.1016\/S1470-2045(21)00302-8."},{"key":"1101_CR72","doi-asserted-by":"crossref","unstructured":"Li Zhang, Yunpeng Yang, Jian-ji Pan, Xiaozhong Chen, Yan Sun, Hui Wang, Shenhong Qu, Nianyong Chen, Lizhu Lin, Siyang Wang, Qitao Yu, Guihua Wang, Feng Lei, Jiyu Wen, Chenqi Chen, Yanjie Wu, Shiangjiin Leaw WF. RATIONALE-309: Updated progression-free survival (PFS), PFS after next line of treatment, and overall survival from a phase 3 double-blind trial of tislelizumab versus placebo, plus chemotherapy, as first-line treatment for recurrent\/metastatic nasopharyn. J Clin Oncol. 2022;40(suppl 36; asbtr 384950).","DOI":"10.1200\/JCO.2022.40.36_suppl.384950"},{"key":"1101_CR73","doi-asserted-by":"publisher","unstructured":"Bossi P, Chan AT, Even C, Machiels J, Guidelines E. SPECIAL ARTICLE ESMO e EURACAN Clinical Practice Guideline update for nasopharyngeal carcinoma\u202f: adjuvant therapy and fi rst-line treatment of recurrent \/ metastatic disease. Ann Oncol [Internet]. 2022;xxx(xxx):3\u20136. Available from: https:\/\/doi.org\/10.1016\/j.annonc.2022.11.011.","DOI":"10.1016\/j.annonc.2022.11.011."},{"key":"1101_CR74","doi-asserted-by":"crossref","unstructured":"Chan A, Lee V, Hong R, Ahn M, Chong W, Kim S. 858O - Results of KEYNOTE-122: A phase III study of pembrolizumab (pembro) monotherapy vs chemotherapy (chemo) for platinum-pretreated, recurrent or metastatic (R\/M) nasopharyngeal carcinoma (NPC). Ann Oncol. 2021;32((suppl_5)):S786\u2013817.","DOI":"10.1016\/j.annonc.2021.08.1268"},{"issue":"14","key":"1101_CR75","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1200\/JCO.2017.77.0388","volume":"36","author":"BBY Ma","year":"2018","unstructured":"Ma BBY, Lim WT, Goh BC, Hui EP, Lo KW, Pettinger A, et al. Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an international, multicenter study of the mayo clinic phase 2 consortium (NCI-9742). J Clin Oncol. 2018;36(14):1412\u20138.","journal-title":"J Clin Oncol."},{"key":"1101_CR76","doi-asserted-by":"publisher","unstructured":"Delord J-P, Hollebecque A, De Boer JP, De Greve J, Machiels J-PH, Leidner RS, et al. An open-label, multicohort, phase I\/II study to evaluate nivolumab in patients with virus-associated tumors (CheckMate 358): efficacy and safety in recurrent or metastatic (R\/M) nasopharyngeal carcinoma (NPC). J Clin Oncol [Internet]. 2017;35(15_suppl):6025. Available from: https:\/\/doi.org\/10.1200\/JCO.2017.35.15_suppl.6025.","DOI":"10.1200\/JCO.2017.35.15_suppl.6025"},{"issue":"7","key":"1101_CR77","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1200\/JCO.20.02712","volume":"39","author":"FH Wang","year":"2021","unstructured":"Wang FH, Wei XL, Feng J, Li Q, Xu N, Hu XC, et al. Efficacy, safety, and correlative biomarkers of toripalimab in previously treated recurrent or metastatic nasopharyngeal carcinoma: a phase ii clinical trial (POLARIS-02). J Clin Oncol. 2021;39(7):704\u201312.","journal-title":"J Clin Oncol"},{"key":"1101_CR78","doi-asserted-by":"publisher","unstructured":"Fang W, Yang Y, Ma Y, Hong S, Lin L, He X, et al. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. Lancet Oncol [Internet]. 2018;19(10):1338\u201350. Available from: https:\/\/doi.org\/10.1016\/S1470-2045(18)30495-9.","DOI":"10.1016\/S1470-2045(18)30495-9."},{"issue":"12","key":"1101_CR79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jitc-2021-003790","volume":"9","author":"Y Yang","year":"2021","unstructured":"Yang Y, Zhou T, Chen X, Li J, Pan J, He X, et al. Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study). J Immunother Cancer. 2021;9(12):1\u20138.","journal-title":"J Immunother Cancer"},{"key":"1101_CR80","doi-asserted-by":"publisher","unstructured":"Lim DW-T, Wang H-M, Li S-H, Ngan R, Dechaphunkul A, Zhang L, et al. Abstract CT150: Phase II study of spartalizumab (PDR001) vs chemotherapy (CT) in patients with recurrent\/metastatic nasopharyngeal cancer (NPC). Cancer Res [Internet]. 2019;79(13_Supplement):CT150\u2013CT150. Available from: https:\/\/doi.org\/10.1158\/1538-7445.AM2019-CT150.","DOI":"10.1158\/1538-7445.AM2019-CT150"},{"issue":"1","key":"1101_CR81","first-page":"27","volume":"20","author":"SF Leung","year":"1991","unstructured":"Leung SF, Teo PM, Shiu WW, Tsao SY, Leung TW. Clinical features and management of distant metastases of nasopharyngeal carcinoma. J Otolaryngol. 1991;20(1):27\u20139.","journal-title":"J Otolaryngol"},{"issue":"12","key":"1101_CR82","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1002\/(SICI)1097-0142(19960615)77:12<2423::AID-CNCR2>3.0.CO;2-N","volume":"77","author":"PM Teo","year":"1996","unstructured":"Teo PM, Kwan WH, Lee WY, Leung SF, Johnson PJ. Prognosticators determining survival subsequent to distant metastasis from nasopharyngeal carcinoma. Cancer. 1996;77(12):2423\u201331.","journal-title":"Cancer"},{"issue":"11","key":"1101_CR83","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1158\/1535-7163.MCT-13-0010","volume":"12","author":"JPH Chow","year":"2013","unstructured":"Chow JPH, Man WY, Mao M, Chen H, Cheung F, Nicholls J, et al. PARP1 Is overexpressed in nasopharyngeal carcinoma and its inhibition enhances radiotherapy. Mol Cancer Ther. 2013;12(11):2517\u201328.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"1101_CR84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12929-019-0507-z","volume":"26","author":"Z Wang","year":"2019","unstructured":"Wang Z, Zuo W, Zeng Q, Qian Y, Li Y, Liu C, et al. Loss of NFBD1\/MDC1 disrupts homologous recombination repair and sensitizes nasopharyngeal carcinoma cells to PARP inhibitors. J Biomed Sci. 2019;26(1):1\u201313.","journal-title":"J Biomed Sci"},{"issue":"2","key":"1101_CR85","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1046\/j.1365-2559.2002.01436.x","volume":"41","author":"TC Putti","year":"2002","unstructured":"Putti TC, To KF, Hsu HC, Chan ATC, Lai GM, Tse G, et al. Expression of epidermal growth factor receptor in head and neck cancers correlates with clinical progression: a multicentre immunohistochemical study in the Asia-Pacific region. Histopathology. 2002;41(2):144\u201351.","journal-title":"Histopathology"},{"issue":"10","key":"1101_CR86","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1002\/hed.10307","volume":"25","author":"BBY Ma","year":"2003","unstructured":"Ma BBY, Poon TCW, To KF, Zee B, Mo FKF, Chan CML, et al. Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma - a prospective study. Head Neck. 2003;25(10):864\u201372.","journal-title":"Head Neck"},{"issue":"1","key":"1101_CR87","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1097\/00005537-200401000-00029","volume":"114","author":"JL Leong","year":"2004","unstructured":"Leong JL, Loh KS, Putti TC, Goh BC, Tan LKS. Epidermal growth factor receptor in undifferentiated carcinoma of the nasopharynx. Laryngoscope. 2004;114(1):153\u20137.","journal-title":"Laryngoscope"},{"issue":"10","key":"1101_CR88","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1200\/JCO.2003.10.051","volume":"21","author":"EEW Cohen","year":"2003","unstructured":"Cohen EEW, Rosen F, Stadler WM, Recant W, Stenson K, Huo D, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2003;21(10):1980\u20137.","journal-title":"J Clin Oncol"},{"key":"1101_CR89","doi-asserted-by":"publisher","unstructured":"Chua DTT, Wei WI, Wong MP, Sham JST, Nicholls J, Au GKH. Phase II study of gefitinib for the treatment of recurrent and metastatic nasopharyngeal carcinoma. Head Neck [Internet]. 2008;30(7):863\u20137. Available from: https:\/\/doi.org\/10.1002\/hed.20792.","DOI":"10.1002\/hed.20792."},{"issue":"1","key":"1101_CR90","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00280-007-0575-8","volume":"62","author":"B Ma","year":"2008","unstructured":"Ma B, Hui EP, King A, To KF, Mo F, Leung SF, et al. A phase II study of patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma Epstein-Barr virus DNA as a biomarker of efficacy. Cancer Chemother Pharmacol. 2008;62(1):59\u201364.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"8","key":"1101_CR91","first-page":"2595","volume":"8","author":"EP Hui","year":"2002","unstructured":"Hui EP, Chan ATC, Pezzella F, Turley H, To K-F, Poon TCW, et al. Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin Cancer Res Off J Am Assoc Cancer Res. 2002;8(8):2595\u2013604.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"1","key":"1101_CR92","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.virusres.2005.07.010","volume":"115","author":"SM Krishna","year":"2006","unstructured":"Krishna SM, James S, Balaram P. Expression of VEGF as prognosticator in primary nasopharyngeal cancer and its relation to EBV status. Virus Res. 2006;115(1):85\u201390.","journal-title":"Virus Res"},{"issue":"5","key":"1101_CR93","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/nrd1381","volume":"3","author":"N Ferrara","year":"2004","unstructured":"Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3(5):391\u2013400.","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"1101_CR94","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1200\/JCO.2005.06.081","volume":"23","author":"DJ Hicklin","year":"2005","unstructured":"Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23(5):1011\u201327.","journal-title":"J Clin Oncol."},{"issue":"24","key":"1101_CR95","doi-asserted-by":"publisher","first-page":"3766","DOI":"10.1200\/JCO.2006.10.2871","volume":"25","author":"C Elser","year":"2007","unstructured":"Elser C, Siu LL, Winquist E, Agulnik M, Pond GR, Chin SF, et al. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol. 2007;25(24):3766\u201373.","journal-title":"J Clin Oncol."},{"issue":"4","key":"1101_CR96","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1093\/annonc\/mds581","volume":"24","author":"C Xue","year":"2013","unstructured":"Xue C, Huang Y, Huang PY, Yu QT, Pan JJ, Liu LZ, et al. Phase ii study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma. Ann Oncol. 2013;24(4):1055\u201361.","journal-title":"Ann Oncol."},{"issue":"16","key":"1101_CR97","doi-asserted-by":"publisher","first-page":"5481","DOI":"10.1158\/1078-0432.CCR-10-3409","volume":"17","author":"WT Lim","year":"2011","unstructured":"Lim WT, Ng QS, Ivy P, Leong SS, Singh O, Chowbay B, et al. A phase II study of pazopanib in asian patients with recurrent\/metastatic nasopharyngeal carcinoma. Clin Cancer Res. 2011;17(16):5481\u20139.","journal-title":"Clin Cancer Res."},{"issue":"6","key":"1101_CR98","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1093\/annonc\/mdq629","volume":"22","author":"EP Hui","year":"2011","unstructured":"Hui EP, Ma BBY, King AD, Mo F, Chan SL, Kam MKM, et al. Hemorrhagic complications in a phase II study of sunitinib in patients of nasopharyngeal carcinoma who has previously received high-dose radiation. Ann Oncol. 2011;22(6):1280\u20137.","journal-title":"Ann Oncol."},{"issue":"5","key":"1101_CR99","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1158\/1078-0432.CCR-17-1667","volume":"24","author":"EP Hui","year":"2018","unstructured":"Hui EP, Ma BBY, Loong HHF, Mo F, Li L, King AD, et al. Efficacy, safety, and pharmacokinetics of axitinib in nasopharyngeal carcinoma: a preclinical and phase II correlative study. Clin Cancer Res. 2018;24(5):1030\u20137.","journal-title":"Clin Cancer Res."},{"issue":"6","key":"1101_CR100","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1007\/s10637-020-00925-2","volume":"38","author":"L Li","year":"2020","unstructured":"Li L, Kong F, Zhang L, Li X, Fu X, Wang X, et al. Apatinib, a novel VEGFR-2 tyrosine kinase inhibitor, for relapsed and refractory nasopharyngeal carcinoma: data from an open-label, single-arm, exploratory study. Invest New Drugs. 2020;38(6):1847\u201353.","journal-title":"Invest New Drugs."},{"issue":"1","key":"1101_CR101","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/ijc.1430","volume":"94","author":"D Chua","year":"2001","unstructured":"Chua D, Huang J, Zheng B, Lau SY, Luk W, Kwong DLW, et al. Adoptive transfer of autologous Epstein-Barr virus-specific cytotoxic T cells for nasopharyngeal carcinoma. Int J Cancer. 2001;94(1):73\u201380.","journal-title":"Int J Cancer."},{"issue":"5","key":"1101_CR102","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1182\/blood-2004-07-2975","volume":"105","author":"KCM Straathof","year":"2005","unstructured":"Straathof KCM, Bollard CM, Popat U, Huls MH, Lopez T, Morriss MC, et al. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood. 2005;105(5):1898\u2013904.","journal-title":"Blood."},{"issue":"35","key":"1101_CR103","doi-asserted-by":"publisher","first-page":"8942","DOI":"10.1200\/JCO.2005.02.6195","volume":"23","author":"P Comoli","year":"2005","unstructured":"Comoli P, Pedrazzoli P, Maccario R, Basso S, Carminati O, Labirio M, et al. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. J Clin Oncol. 2005;23(35):8942\u20139.","journal-title":"J Clin Oncol."},{"issue":"9","key":"1101_CR104","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1097\/CJI.0b013e3181f3cbf4","volume":"33","author":"CU Louis","year":"2010","unstructured":"Louis CU, Straathof K, Bollard CM, Ennamuri S, Gerken C, Lopez TT, et al. Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. J Immunother. 2010;33(9):983\u201390.","journal-title":"J Immunother."},{"issue":"14","key":"1101_CR105","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1002\/cncr.30541","volume":"123","author":"J Huang","year":"2017","unstructured":"Huang J, Fogg M, Wirth LJ, Daley H, Ritz J, Posner MR, et al. Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma. Cancer. 2017;123(14):2642\u201350.","journal-title":"Cancer."},{"issue":"1","key":"1101_CR106","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/mt.2013.242","volume":"22","author":"WK Chia","year":"2014","unstructured":"Chia WK, Teo M, Wang WW, Lee B, Ang SF, Tai WM, et al. Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and\/or locally recurrent nasopharyngeal carcinoma. Mol Ther. 2014;22(1):132\u20139.","journal-title":"Mol Ther."},{"key":"1101_CR107","doi-asserted-by":"crossref","unstructured":"Toh HC, Yang M, Wang H, Hsieh C, Chitapanarux I. 652O - Randomized phase III VANCE study: gemcitabine and carboplatin (GC) followed by Epstein Barr virus-specific autologous cytotoxic T lymphocytes (EBV-CTL) versus the same chemotherapy as first-line treatment for advanced nasopharyngeal carcinoma (NPC). Ann Oncol. 2022;33(suppl_7):S295\u2013322.","DOI":"10.1016\/j.annonc.2022.07.776"},{"issue":"2","key":"1101_CR108","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4161\/23723556.2014.976507","volume":"4","author":"J Li","year":"2015","unstructured":"Li J, Chen QY, He J, Li ZL, Tang XF, Chen SP, et al. Phase I trial of adoptively transferred tumor-infiltrating lymphocyte immunotherapy following concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. Oncoimmunology. 2015;4(2):1\u201310.","journal-title":"Oncoimmunology."},{"issue":"23","key":"1101_CR109","first-page":"6952","volume":"62","author":"C-L Lin","year":"2002","unstructured":"Lin C-L, Lo W-F, Lee T-H, Ren Y, Hwang S-L, Cheng Y-F, et al. Immunization with Epstein-Barr Virus (EBV) peptide-pulsed dendritic cells induces functional CD8+ T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma. Cancer Res. 2002;62(23):6952\u20138.","journal-title":"Cancer Res."},{"issue":"2","key":"1101_CR110","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1128\/JVI.78.2.768-778.2004","volume":"78","author":"GS Taylor","year":"2004","unstructured":"Taylor GS, Haigh TA, Gudgeon NH, Phelps RJ, Lee SP, Steven NM, et al. Dual stimulation of Epstein-Barr virus (EBV)-specific CD4 + - and CD8 + -T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma. J Virol. 2004;78(2):768\u201378.","journal-title":"J Virol"},{"issue":"6","key":"1101_CR111","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1158\/0008-5472.CAN-12-2448","volume":"73","author":"EP Hui","year":"2013","unstructured":"Hui EP, Taylor GS, Jia H, Ma BBY, Chan SL, Ho R, et al. Phase I trial of recombinant modified vaccinia ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patients. Cancer Res. 2013;73(6):1676\u201388.","journal-title":"Cancer Res"},{"issue":"19","key":"1101_CR112","doi-asserted-by":"publisher","first-page":"5009","DOI":"10.1158\/1078-0432.CCR-14-1122-T","volume":"20","author":"GS Taylor","year":"2015","unstructured":"Taylor GS, Jia H, Harrington K, Lee LW, Turner J, Price DA, et al. Europe PMC Funders Group Europe PMC Funders Author Manuscripts A recombinant modified vaccinia Ankara vaccine encoding Epstein-Barr virus ( EBV ) target antigens\u202f: a phase I trial in UK patients with EBV-positive cancer. Clin Cancer Res. 2015;20(19):5009\u201322.","journal-title":"Clin Cancer Res."},{"issue":"4","key":"1101_CR113","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1093\/annonc\/mdr341","volume":"23","author":"WK Chia","year":"2012","unstructured":"Chia WK, Wang WW, Teo M, Tai WM, Lim WT, Tan EH, et al. A phase II study evaluating the safety and efficacy of an adenovirus-\u03b4LMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma. Ann Oncol. 2012;23(4):997\u20131005.","journal-title":"Ann Oncol."},{"issue":"3","key":"1101_CR114","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1097\/CJI.0b013e31828bd87b","volume":"36","author":"F Li","year":"2013","unstructured":"Li F, Song D, Lu Y, Zhu H, Chen Z, He X. Delayed-type hypersensitivity (DTH) immune response related with EBV-DNA in nasopharyngeal carcinoma treated with autologous dendritic cell vaccination after radiotherapy. J Immunother. 2013;36(3):208\u201314.","journal-title":"J Immunother."},{"key":"1101_CR115","doi-asserted-by":"publisher","unstructured":"Walsh RJ, Nickles EP, Li Y, Dharmadhikari B, Koh M, Ho LP, et al. Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma (NPC). J Clin Oncol [Internet]. 2020;38(15_suppl):6535. Available from: https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.6535.","DOI":"10.1200\/JCO.2020.38.15_suppl.6535"},{"key":"1101_CR116","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.2147\/OTT.S188148","volume":"12","author":"F Perri","year":"2019","unstructured":"Perri F, Della Vittoria Scarpati G, Caponigro F, Ionna F, Longo F, Buonopane S, et al. Management of recurrent nasopharyngeal carcinoma: current perspectives. Onco Targets Ther. 2019;12:1583\u201391.","journal-title":"Onco Targets Ther."},{"issue":"1","key":"1101_CR117","doi-asserted-by":"publisher","first-page":"341","DOI":"10.7150\/jca.2.341","volume":"2","author":"S Basso","year":"2011","unstructured":"Basso S, Zecca M, Merli P, Gurrado A, Secondino S, Quartuccio G, et al. T cell therapy for nasopharyngeal carcinoma. J Cancer. 2011;2(1):341\u20136.","journal-title":"J Cancer."},{"issue":"3","key":"1101_CR118","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1089\/humc.2013.144","volume":"24","author":"MCI Van Schalkwyk","year":"2013","unstructured":"Van Schalkwyk MCI, Papa SE, Jeannon JP, Urbano TG, Spicer JF, Maher J. Design of a phase i clinical trial to evaluate intratumoral delivery of ErbB-targeted chimeric antigen receptor T-cells in locally advanced or recurrent head and neck cancer. Hum Gene Ther Clin Dev. 2013;24(3):134\u201342.","journal-title":"Hum Gene Ther Clin Dev."},{"issue":"6","key":"1101_CR119","doi-asserted-by":"publisher","first-page":"468","DOI":"10.7555\/JBR.28.20140066","volume":"28","author":"X Tang","year":"2014","unstructured":"Tang X, Zhou Y, Li W, Tang Q, Chen R, Zhu J, et al. T cells expressing a LMP1-specific chimeric antigen receptor mediate antitumor effects against LMP1-positive nasopharyngeal carcinoma cells in vitro and in vivo. J Biomed Res. 2014;28(6):468\u201375.","journal-title":"J Biomed Res."},{"issue":"9","key":"1101_CR120","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/nrd4663","volume":"14","author":"HL Kaufman","year":"2015","unstructured":"Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2015;14(9):642\u201362.","journal-title":"Nat Rev Drug Discov."},{"key":"1101_CR121","doi-asserted-by":"crossref","unstructured":"Olubukola A, Siu LL. New drugs for recurrent or metastatic nasopharyngeal cancer. In: Critical Issues in Head and Neck Oncology. 2021. p. 337\u201354.","DOI":"10.1007\/978-3-030-63234-2_23"},{"key":"1101_CR122","doi-asserted-by":"crossref","unstructured":"Garber K. China approves world\u2019s first oncolytic virus therapy for cancer treatment. Vol. 98, Journal of the National Cancer Institute. United States; 2006. p. 298\u2013300.","DOI":"10.1093\/jnci\/djj111"},{"issue":"12","key":"1101_CR123","first-page":"1666","volume":"23","author":"Z-J Xia","year":"2004","unstructured":"Xia Z-J, Chang J-H, Zhang L, Jiang W-Q, Guan Z-Z, Liu J-W, et al. Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus. Ai Zheng. 2004;23(12):1666\u201370.","journal-title":"Ai Zheng."},{"key":"1101_CR124","doi-asserted-by":"crossref","unstructured":"Wang JN, Hu P, Zeng MS, Liu R Bin. Anti-tumor effect of oncolytic herpes simplex virus G47delta on human nasopharyngeal carcinoma. Chin J Cancer. 2011;30(12):831\u201341.","DOI":"10.5732\/cjc.011.10301"},{"key":"1101_CR125","doi-asserted-by":"publisher","unstructured":"Mondal M, Guo J, He P, Zhou D. Recent advances of oncolytic virus in cancer therapy. Hum Vaccines Immunother [Internet]. 2020;16(10):2389\u2013402. Available from: https:\/\/doi.org\/10.1080\/21645515.2020.1723363.","DOI":"10.1080\/21645515.2020.1723363."},{"key":"1101_CR126","doi-asserted-by":"publisher","unstructured":"Smith C, Lee V, Schuessler A, Beagley L, Rehan S, Tsang J, et al. Pre-emptive and therapeutic adoptive immunotherapy for nasopharyngeal carcinoma: phenotype and effector function of T cells impact on clinical response. Oncoimmunology [Internet]. 2017;6(2):1\u20139. Available from: https:\/\/doi.org\/10.1080\/2162402X.2016.1273311.","DOI":"10.1080\/2162402X.2016.1273311."}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-023-01101-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-023-01101-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-023-01101-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T05:58:27Z","timestamp":1729576707000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-023-01101-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,15]]},"references-count":126,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["1101"],"URL":"https:\/\/doi.org\/10.1007\/s11864-023-01101-3","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,15]]},"assertion":[{"value":"24 April 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"All authors reported any conflicts of interest, if any, in their respective ICMJE form. None of the reported conflicts of interests are associated with the current manuscript. Juan Jose Juarez-Vignon Whaley, Michelle Afkhami, Mykola Onyshckenko, Sagus Sampath, Arya Amini, and Diana Bell have no potential conflicts of interest to report. Erminia Massarelli: Honoraria \u2014 AstraZeneca, Merck; Consulting\/Advisory Role \u2014 Genentech\/Roche, Merck, Lilly, Jansen Scientific Affairs, Sanofi, Bristol Myers Squibb Foundation, Daiichi Sankyo Co, Abbvie; Speakers\u00b4 Bureau: Merck, AstraZeneca, Takeda, Lilly, Mirati Therapeutics; Research Funding: Merch, AstraZeneca, Pfizer, Tessa Therapeutics, Bristol-Myers Squibb, GlaxoSmithKline, Genentech. Travel, Acommodotions, Expenses: Bristol-Myers Squibb, Merck, Genentech\/Roche, Pfizer, AstraZeneca. Victoria M. Villaflor: Research Funding \u2014 Takeda; Stock Ownership \u2014 Johnson and Johnson; Advisory Board \u2014 Astra Zeneca.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}